Results of Intravitreal Dexamethasone Implant and Anti-VEGF Treatment in Treatment of Macular Edema Secondary to Branch Retinal vein Occlusion

Abstract

Purpose: To evaluate the changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) in patients who received intravitreal dexamethasone implant (DEX-implant) and anti-vascular endothelial growth factor (VEGF) in the treatment of macular edema secondary Branch Retinal Vein Occlusion (BRVO). Materials and Methods: In this interventional, retrospective, single-center study, BCVA and CMT at baseline and on months 6, 9, 12 and 24 as well as mean number of injections and adverse effects were evaluated in 91 eyes with macular edema secondary to BRVO which were treated via intravitreal route. Results: In our study, 24 patients received intravitreal DEX-implant (group 1) and 46 patients received intravitreal anti-VEGF (group 2). The treatment was switched in 21 patients who were resistant to treatment (group 3). The mean number of injections was 2.13 (± 1.2) in group 1, 4 (± 1.8) in group 2 and 5.6 (± 3) in group 3. In all three groups, the percent change in BCVA and CMT was found to be significant on months 6, 9, 12 and 24 when compared to baseline (p